[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-001", "question": "A 16-year-old female presents with episodes of muscle weakness and palpitations. Physical exam reveals low-set ears, micrognathia, and clinodactyly. ECG demonstrates frequent PVCs, a QTc of 490 ms, and prominent U waves. Genetic testing confirms a loss-of-function mutation in KCNJ2. She continues to have frequent non-sustained ventricular tachycardia despite beta-blocker therapy. What is the most appropriate pharmacologic management for her arrhythmia?", "options": ["Option A: Nadolol", "Option B: Amiodarone", "Option C: Flecainide", "Option D: Mexiletine", "Option E: Verapamil"], "answer": "C", "answer_index": 2, "explanation": "This patient has Andersen-Tawil Syndrome (LQT7), characterized by the triad of periodic paralysis, dysmorphic features, and QT/U wave abnormalities. Unlike other Long QT Syndromes where sodium channel blockers are often contraindicated, Flecainide is uniquely effective in suppressing the ventricular arrhythmias associated with KCNJ2 mutations.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (logically valid). The stem provides a classic Andersen‑Tawil syndrome picture (KCNJ2 loss‑of‑function, dysmorphic features, prolonged QTc with prominent U waves) and specifies refractory ventricular ectopy despite β‑blocker therapy. The question asks for the most appropriate pharmacologic next step. Among the choices, flecainide (class Ic) is the only agent with evidence of efficacy in KCNJ2‑related arrhythmias; β‑blocker (nadolol) is already failing, amiodarone and verapamil are not indicated and may worsen QT prolongation, and mexiletine has less supporting data. Thus a single best answer is defensible and matches the key. Medical accuracy: The answer is consistent with current literature (flecainide reduces ventricular arrhythmias in ATS). The rationale, however, incorrectly states that sodium‑channel blockers are contraindicated in other long‑QT syndromes; they are actually used in LQT3. This is a minor factual imprecision but does not alter the correct choice. Minimal fix: Revise the rationale to delete the inaccurate contraindication statement and simply note that flecainide has specific efficacy in KCNJ2 mutations.\",\n\"medical_accuracy_score\":   \t\"4\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (logically valid). The stem provides a classic Andersen‑Tawil syndrome picture (KCNJ2 loss‑of‑function, dysmorphic features, prolonged QTc with prominent U waves) and specifies refractory ventricular ectopy despite β‑blocker therapy. The question asks for the most appropriate pharmacologic next step. Among the choices, flecainide (class Ic) is the only agent with evidence of efficacy in KCNJ2‑related arrhythmias; β‑blocker (nadolol) is already failing, amiodarone and verapamil are not indicated and may worsen QT prolongation, and mexiletine has less supporting data. Thus a single best answer is defensible and matches the key. Medical accuracy: The answer is consistent with current literature (flecainide reduces ventricular arrhythmias in ATS). The rationale, however, incorrectly states that sodium‑channel blockers are contraindicated in other long‑QT syndromes; they are actually used in LQT3. This is a minor factual imprecision but does not alter the correct choice. Minimal fix: Revise the rationale to delete the inaccurate contraindication statement and simply note that flecainide has specific efficacy in KCNJ2 mutations.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-002", "question": "A 55-year-old man presents with bone pain and exophthalmos. CT imaging reveals perinephric infiltration with a 'hairy kidney' appearance and osteosclerotic lesions in the distal femur. Biopsy of the retroperitoneal tissue shows infiltration by foamy histiocytes that are CD68+ and CD1a-. Molecular testing reveals a BRAF V600E mutation. Which therapeutic agent is most indicated?", "options": ["Option A: Rituximab", "Option B: High-dose Prednisone", "Option C: Vemurafenib", "Option D: Methotrexate", "Option E: Infliximab"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation (hairy kidney, osteosclerosis, exophthalmos) and pathology (CD68+, CD1a- foamy histiocytes) are diagnostic of Erdheim-Chester Disease (ECD), a non-Langerhans cell histiocytosis. Over 50% of cases carry the BRAF V600E mutation. Targeted therapy with a BRAF inhibitor (Vemurafenib) is the treatment of choice for BRAF-positive ECD, superior to empiric immunosuppression.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The stem provides classic Erdheim-Chester disease (ECD) features: osteosclerotic bone lesions, perinephric hairy kidney infiltration, orbital involvement causing exophthalmos, and foamy CD68+/CD1a- histiocytes. The BRAF V600E mutation, present in >50% of ECD cases, mandates targeted therapy. Key discriminating clue is the molecular result, which directly points to BRAF inhibition. Vemurafenib is the established first-line treatment for BRAF-mutated ECD per current guidelines, making option C uniquely defensible. Alternatives fail: rituximab (anti-CD20) targets B cells, not histiocytes; high-dose prednisone and methotrexate are nonspecific immunosuppression inferior to targeted therapy; infliximab (anti-TNF) lacks evidence in ECD. No internal contradictions exist, and options permit clear discrimination. Medical accuracy is excellent: the immunophenotype, imaging descriptors, and therapeutic recommendation align with consensus. Minor enhancement could specify first-line in the stem (most appropriate first-line therapy), but this does not affect answer defensibility. The item is board-relevant and educationally sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The stem provides classic Erdheim-Chester disease (ECD) features: osteosclerotic bone lesions, perinephric hairy kidney infiltration, orbital involvement causing exophthalmos, and foamy CD68+/CD1a- histiocytes. The BRAF V600E mutation, present in >50% of ECD cases, mandates targeted therapy. Key discriminating clue is the molecular result, which directly points to BRAF inhibition. Vemurafenib is the established first-line treatment for BRAF-mutated ECD per current guidelines, making option C uniquely defensible. Alternatives fail: rituximab (anti-CD20) targets B cells, not histiocytes; high-dose prednisone and methotrexate are nonspecific immunosuppression inferior to targeted therapy; infliximab (anti-TNF) lacks evidence in ECD. No internal contradictions exist, and options permit clear discrimination. Medical accuracy is excellent: the immunophenotype, imaging descriptors, and therapeutic recommendation align with consensus. Minor enhancement could specify first-line in the stem (most appropriate first-line therapy), but this does not affect answer defensibility. The item is board-relevant and educationally sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-003", "question": "A 32-year-old G1P0 woman at 35 weeks gestation presents with nausea, vomiting, and jaundice. Labs show AST 300 U/L, ALT 350 U/L, Platelets 80,000/mm3, Glucose 45 mg/dL, and INR 2.5. A diagnosis of Acute Fatty Liver of Pregnancy (AFLP) is made, and the infant is delivered urgently. To prevent sudden death in the neonate, which specific screening test should be prioritized?", "options": ["Option A: Serum ammonia and lactate", "Option B: Plasma acylcarnitine profile", "Option C: Galactose-1-phosphate uridyltransferase", "Option D: Very long-chain fatty acids (VLCFA)", "Option E: Hemoglobin electrophoresis"], "answer": "B", "answer_index": 1, "explanation": "Maternal AFLP is strongly associated with fetal Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Fetal fatty acid oxidation defects cause accumulation of metabolites that cross the placenta and overwhelm the maternal liver. The neonate is at high risk for hypoketotic hypoglycemia and sudden death; an acylcarnitine profile is diagnostic.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\": The question asks which screening test should be prioritized in a neonate born to a mother with Acute Fatty Liver of Pregnancy (AFLP) to prevent sudden death. The stem correctly identifies that AFLP is associated with fetal LCHAD deficiency, a long-chain fatty acid oxidation disorder. The key discriminating finding is the maternal AFLP diagnosis, which triggers concern for an underlying fetal fatty acid oxidation defect. The keyed answer (B) plasma acylcarnitine profile is the standard newborn screening test for fatty acid oxidation disorders, including LCHAD deficiency, and is essential to detect the risk of hypoketotic hypoglycemia and sudden death. Option A (serum ammonia and lactate) is nonspecific and not the primary screening tool for this condition. Option C (galactose-1-phosphate uridyltransferase) tests for galactosemia, unrelated to AFLP. Option D (VLCFA) is used for peroxisomal disorders (e.g., adrenoleukodystrophy), not mitochondrial fatty acid oxidation defects. Option E (hemoglobin electrophoresis) screens for hemoglobinopathies, also unrelated. The item is logically valid: the stem provides a clear clinical scenario, the answer is unique and defensible, and the key matches that best answer. The medical content is accurate and aligns with current neonatal screening guidelines for fatty acid oxidation disorders. No contradictions or missing critical details are present.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ": The question asks which screening test should be prioritized in a neonate born to a mother with Acute Fatty Liver of Pregnancy (AFLP) to prevent sudden death. The stem correctly identifies that AFLP is associated with fetal LCHAD deficiency, a long-chain fatty acid oxidation disorder. The key discriminating finding is the maternal AFLP diagnosis, which triggers concern for an underlying fetal fatty acid oxidation defect. The keyed answer (B) plasma acylcarnitine profile is the standard newborn screening test for fatty acid oxidation disorders, including LCHAD deficiency, and is essential to detect the risk of hypoketotic hypoglycemia and sudden death. Option A (serum ammonia and lactate) is nonspecific and not the primary screening tool for this condition. Option C (galactose-1-phosphate uridyltransferase) tests for galactosemia, unrelated to AFLP. Option D (VLCFA) is used for peroxisomal disorders (e.g., adrenoleukodystrophy), not mitochondrial fatty acid oxidation defects. Option E (hemoglobin electrophoresis) screens for hemoglobinopathies, also unrelated. The item is logically valid: the stem provides a clear clinical scenario, the answer is unique and defensible, and the key matches that best answer. The medical content is accurate and aligns with current neonatal screening guidelines for fatty acid oxidation disorders. No contradictions or missing critical details are present.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-004", "question": "A 24-year-old male with HIV and known G6PD deficiency develops cyanosis and dyspnea after receiving dapsone. SpO2 is 85% and arterial blood is chocolate-colored. Methemoglobin level is 25%. He is inadvertently treated with methylene blue, after which his condition deteriorates with evidence of acute hemolysis and worsening hypoxia. What is the most appropriate next step in management?", "options": ["Option A: Repeat Methylene Blue dose", "Option B: High-dose Ascorbic Acid (Vitamin C)", "Option C: Exchange transfusion", "Option D: Hyperbaric oxygen therapy", "Option E: Hydroxocobalamin"], "answer": "C", "answer_index": 2, "explanation": "Methylene blue requires NADPH (generated via the G6PD pathway) to reduce methemoglobin. In G6PD deficiency, it is ineffective and can induce severe hemolysis (as seen here). Ascorbic acid is too slow for acute severe toxicity. Exchange transfusion is the definitive rescue therapy to rapidly remove the methemoglobin and the offending agent.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). This item tests a high-yield toxicology concept: management of severe methemoglobinemia when methylene blue is contraindicated. Key discriminating findings are: (1) known G6PD deficiency, (2) dapsone exposure (a classic oxidant drug), (3) methemoglobin 25% with cyanosis and chocolate-colored blood, and (4) acute hemolysis after methylene blue administration. These features establish that methylene blue is ineffective and harmful, eliminating option A. Option B (high-dose ascorbic acid) is pharmacologically correct but too slow for acute severe toxicity with worsening hypoxia. Option D (hyperbaric oxygen) is not indicated for methemoglobinemia. Option E (hydroxocobalamin) treats cyanide poisoning, not methemoglobinemia. Exchange transfusion (C) is the definitive rescue therapy to rapidly remove methemoglobin and residual dapsone, consistent with toxicology guidelines for life-threatening cases where standard therapy fails. The item contains no internal contradictions, provides sufficient detail for a unique best answer, and the key is correct. Medical accuracy is excellent and board-relevant. Minimal fix: none required.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). This item tests a high-yield toxicology concept: management of severe methemoglobinemia when methylene blue is contraindicated. Key discriminating findings are: (1) known G6PD deficiency, (2) dapsone exposure (a classic oxidant drug), (3) methemoglobin 25% with cyanosis and chocolate-colored blood, and (4) acute hemolysis after methylene blue administration. These features establish that methylene blue is ineffective and harmful, eliminating option A. Option B (high-dose ascorbic acid) is pharmacologically correct but too slow for acute severe toxicity with worsening hypoxia. Option D (hyperbaric oxygen) is not indicated for methemoglobinemia. Option E (hydroxocobalamin) treats cyanide poisoning, not methemoglobinemia. Exchange transfusion (C) is the definitive rescue therapy to rapidly remove methemoglobin and residual dapsone, consistent with toxicology guidelines for life-threatening cases where standard therapy fails. The item contains no internal contradictions, provides sufficient detail for a unique best answer, and the key is correct. Medical accuracy is excellent and board-relevant. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-005", "question": "A 3-month-old male presents with generalized erythroderma, lymphadenopathy, hepatosplenomegaly, and chronic diarrhea. CBC reveals eosinophilia and lymphocytosis. Immunophenotyping shows an absence of B cells, but elevated numbers of oligoclonal, activated T cells. Which genetic defect is most consistent with this presentation?", "options": ["Option A: BTK mutation", "Option B: Hypomorphic RAG1/RAG2 mutation", "Option C: CD40 Ligand mutation", "Option D: STAT3 mutation", "Option E: WAS gene mutation"], "answer": "B", "answer_index": 1, "explanation": "This is Omenn Syndrome, a form of 'leaky' Severe Combined Immunodeficiency (SCID). It is caused by hypomorphic mutations in RAG1 or RAG2 that allow for partial V(D)J recombination. This results in the absence of B cells but the development of a restricted, autoreactive T-cell repertoire that infiltrates tissues (erythroderma, hepatosplenomegaly) and causes high IgE/eosinophilia.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict: The keyed answer (B) is the unique best answer. Key stem clues: 3-month-old male with generalized erythroderma, lymphadenopathy, hepatosplenomegaly, chronic diarrhea, eosinophilia, lymphocytosis, absent B cells, and oligoclonal activated T cells. This constellation defines Omenn syndrome, a “leaky” SCID caused by hypomorphic RAG1/RAG2 mutations that permit limited V(D)J recombination. The resulting autoreactive T-cell infiltrate explains the skin, visceral, and hematologic findings. Alternative options are clearly incompatible: BTK deficiency (XLA) lacks erythroderma and eosinophilia; CD40L deficiency preserves B cells and presents with hyper-IgM; STAT3 deficiency (hyper-IgE) does not eliminate B cells; WAS mutations cause thrombocytopenia and eczema but preserve B cells. No internal contradiction or missing data prevents a single best choice. No medical inaccuracies; the description aligns with current immunology consensus. Minor note: the explanation adds high IgE (common in Omenn) though not mentioned in the stem, but this does not affect answer selection. Minimal fix: none required.\",\"medical_accuracy_score\":5,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: The keyed answer (B) is the unique best answer. Key stem clues: 3-month-old male with generalized erythroderma, lymphadenopathy, hepatosplenomegaly, chronic diarrhea, eosinophilia, lymphocytosis, absent B cells, and oligoclonal activated T cells. This constellation defines Omenn syndrome, a “leaky” SCID caused by hypomorphic RAG1/RAG2 mutations that permit limited V(D)J recombination. The resulting autoreactive T-cell infiltrate explains the skin, visceral, and hematologic findings. Alternative options are clearly incompatible: BTK deficiency (XLA) lacks erythroderma and eosinophilia; CD40L deficiency preserves B cells and presents with hyper-IgM; STAT3 deficiency (hyper-IgE) does not eliminate B cells; WAS mutations cause thrombocytopenia and eczema but preserve B cells. No internal contradiction or missing data prevents a single best choice. No medical inaccuracies; the description aligns with current immunology consensus. Minor note: the explanation adds high IgE (common in Omenn) though not mentioned in the stem, but this does not affect answer selection. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-006", "question": "A 4-month-old infant presents with failure to thrive and diaphoresis during feeding. ECG reveals deep Q waves in leads I, aVL, and V5-V6. Echocardiography demonstrates a dilated left ventricle. During color Doppler interrogation of the coronary arteries, which flow pattern confirms the diagnosis of Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA)?", "options": ["Option A: Diastolic flow from the aorta into the left coronary artery", "Option B: Systolic flow from the pulmonary artery into the left coronary artery", "Option C: Retrograde flow from the left coronary artery into the pulmonary artery", "Option D: Continuous flow from the aorta to the pulmonary artery", "Option E: Turbulent high-velocity flow at the left coronary ostium"], "answer": "C", "answer_index": 2, "explanation": "In the infant/adult type of ALCAPA, pulmonary vascular resistance drops, causing flow reversal. Blood flows from the aorta to the Right Coronary Artery, through collaterals to the Left Coronary Artery, and then retrograde into the low-pressure Pulmonary Artery (coronary steal). The hallmark is retrograde flow into the PA.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict: Correct best answer. Key discriminating clues: 4-month-old infant with failure to thrive and diaphoretic feeding (infantile ALCAPA syndrome); ECG showing deep Q waves in I, aVL, V5-V6 (anterolateral infarction); dilated left ventricle on echo (ischemic cardiomyopathy). The pathophysiologic hallmark of ALCAPA is postnatal drop in pulmonary vascular resistance causing pressure gradient reversal, resulting in coronary steal: blood flows from aorta → RCA → collaterals → LCA → low-pressure pulmonary artery. Color Doppler confirmation requires demonstrating retrograde flow from the left coronary artery into the pulmonary artery, as described in option C. Alternative choices are definitively incorrect: option A describes normal diastolic coronary filling; B reflects fetal circulation before PVR decline; D characterizes a patent ductus arteriosus; E is a nonspecific finding. The item contains no internal inconsistencies or critical omissions. Medical content is accurate, current, and aligns with pediatric cardiology consensus. Minimal fix: None required; item is board-examination ready.\",\"medical_accuracy_score\":5,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: Correct best answer. Key discriminating clues: 4-month-old infant with failure to thrive and diaphoretic feeding (infantile ALCAPA syndrome); ECG showing deep Q waves in I, aVL, V5-V6 (anterolateral infarction); dilated left ventricle on echo (ischemic cardiomyopathy). The pathophysiologic hallmark of ALCAPA is postnatal drop in pulmonary vascular resistance causing pressure gradient reversal, resulting in coronary steal: blood flows from aorta → RCA → collaterals → LCA → low-pressure pulmonary artery. Color Doppler confirmation requires demonstrating retrograde flow from the left coronary artery into the pulmonary artery, as described in option C. Alternative choices are definitively incorrect: option A describes normal diastolic coronary filling; B reflects fetal circulation before PVR decline; D characterizes a patent ductus arteriosus; E is a nonspecific finding. The item contains no internal inconsistencies or critical omissions. Medical content is accurate, current, and aligns with pediatric cardiology consensus. Minimal fix: None required; item is board-examination ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-007", "question": "A 60-year-old male presents with nephrotic syndrome. Labs show low serum C3 and normal C4. Kidney biopsy reveals C3-dominant staining on immunofluorescence and a membranoproliferative pattern on light microscopy. Serum protein electrophoresis is negative, but serum free light chain assay shows a kappa:lambda ratio of 5.0. What is the most appropriate treatment to preserve renal function?", "options": ["Option A: Eculizumab", "Option B: Mycophenolate Mofetil", "Option C: Clone-directed chemotherapy (e.g., Bortezomib-based)", "Option D: High-dose steroids alone", "Option E: Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "This patient has C3 Glomerulopathy (C3G) secondary to a Monoclonal Gammopathy of Renal Significance (MGRS). The monoclonal protein acts as an autoantibody (e.g., C3 nephritic factor) driving complement activation. The standard of care is to treat the underlying clone (plasma cell directed therapy) rather than non-specific immunosuppression or complement inhibition alone.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The stem presents classic C3 glomerulopathy (C3G) features (low C3, normal C4, C3-dominant IF, MPGN pattern) with nephrotic syndrome. The critical discriminator is the abnormal serum free light chain ratio (5.0) with negative SPEP, indicating monoclonal gammopathy of renal significance (MGRS) driving complement dysregulation. Current KDIGO and expert consensus recommend treating the underlying B-cell or plasma cell clone in MGRS-associated C3G rather than isolated complement inhibition. Clone-directed therapy (Option C) directly addresses the pathogenic monoclonal protein, while eculizumab (A) would only block complement downstream without removing the trigger. Mycophenolate (B) and steroids alone (D) lack efficacy data in C3G. Plasma exchange (E) is adjunctive at best. No internal contradictions exist; all options are plausible but clearly inferior to C. Medical accuracy is excellent: the pathophysiology linking monoclonal gammopathy to C3G is well-established, and bortezomib-based regimens are standard for plasma cell clones. Minor enhancement could specify 'plasma cell clone' to preempt questions about rituximab for B-cell clones, but the item remains board-valid as written.\",\"logical_false_reason\":\"T\",\"logical_validity\":true,\"medical_accuracy_score\":\"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The stem presents classic C3 glomerulopathy (C3G) features (low C3, normal C4, C3-dominant IF, MPGN pattern) with nephrotic syndrome. The critical discriminator is the abnormal serum free light chain ratio (5.0) with negative SPEP, indicating monoclonal gammopathy of renal significance (MGRS) driving complement dysregulation. Current KDIGO and expert consensus recommend treating the underlying B-cell or plasma cell clone in MGRS-associated C3G rather than isolated complement inhibition. Clone-directed therapy (Option C) directly addresses the pathogenic monoclonal protein, while eculizumab (A) would only block complement downstream without removing the trigger. Mycophenolate (B) and steroids alone (D) lack efficacy data in C3G. Plasma exchange (E) is adjunctive at best. No internal contradictions exist; all options are plausible but clearly inferior to C. Medical accuracy is excellent: the pathophysiology linking monoclonal gammopathy to C3G is well-established, and bortezomib-based regimens are standard for plasma cell clones. Minor enhancement could specify 'plasma cell clone' to preempt questions about rituximab for B-cell clones, but the item remains board-valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-008", "question": "A patient with severe ARDS is ventilated in Assist-Control Volume Control mode. He is deeply sedated but not paralyzed. Ventilator graphics display a time-triggered mandatory breath, followed immediately by a drop in esophageal pressure (diaphragmatic contraction) occurring during the inspiratory phase, which triggers a second breath during exhalation (breath stacking). This phenomenon is best described as:", "options": ["Option A: Double triggering due to flow starvation", "Option B: Reverse triggering", "Option C: Ineffective triggering", "Option D: Premature cycling", "Option E: Auto-triggering"], "answer": "B", "answer_index": 1, "explanation": "Reverse triggering is a form of patient-ventilator dyssynchrony where the passive insufflation from the ventilator mechanically stretches the diaphragm, reflexively inducing a patient respiratory effort (entrainment). If this induced effort is strong enough, it can trigger a second breath (breath stacking). It is distinct from double triggering caused by high patient drive.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\": Validity label: V (Valid). Verdict on keyed answer: Correct best. Key stem clues: deeply sedated but not paralyzed patient with severe ARDS; time-triggered mandatory breath; drop in esophageal pressure (diaphragmatic contraction) during inspiratory phase; second breath triggered during exhalation (breath stacking). These findings specifically describe reverse triggering—ventilator-induced diaphragmatic stretch causing reflexive patient effort. Main logical issue: None. The stem provides sufficient mechanistic detail to differentiate reverse triggering from other dyssynchronies. Main medical accuracy issue: None. The description aligns with current ICU literature: reverse triggering is a reflex response to mechanical insufflation, distinct from flow starvation or auto-triggering. Minimal fix: None required.\",\"logical_false_reason\":\"T\",\"logical_validity\":true,\"medical_accuracy_score\":\"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ": Validity label: V (Valid). Verdict on keyed answer: Correct best. Key stem clues: deeply sedated but not paralyzed patient with severe ARDS; time-triggered mandatory breath; drop in esophageal pressure (diaphragmatic contraction) during inspiratory phase; second breath triggered during exhalation (breath stacking). These findings specifically describe reverse triggering—ventilator-induced diaphragmatic stretch causing reflexive patient effort. Main logical issue: None. The stem provides sufficient mechanistic detail to differentiate reverse triggering from other dyssynchronies. Main medical accuracy issue: None. The description aligns with current ICU literature: reverse triggering is a reflex response to mechanical insufflation, distinct from flow starvation or auto-triggering. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-009", "question": "A 28-year-old G2P2 woman presents 3 months postpartum with extensive ecchymoses and bleeding from a minor cut. Coagulation studies show aPTT 78s and PT 12s. A mixing study fails to correct the aPTT. Factor VIII activity is <1%. Which agent is the most appropriate first-line therapy for acute bleeding control?", "options": ["Option A: Desmopressin (DDAVP)", "Option B: Cryoprecipitate", "Option C: Recombinant Human Factor VIII", "Option D: Recombinant Porcine Factor VIII", "Option E: High-dose Prednisone"], "answer": "D", "answer_index": 3, "explanation": "This is acquired hemophilia A (postpartum), caused by an inhibitor (autoantibody) to Factor VIII. Human Factor VIII (and Cryoprecipitate) will be neutralized by the inhibitor and is ineffective. First-line hemostatic agents are bypassing agents (rFVIIa or FEIBA) or Recombinant Porcine Factor VIII (which has low cross-reactivity with human anti-FVIII antibodies). Prednisone treats the clone but does not stop acute bleeding.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (logically valid). Verdict: Keyed answer D is the correct best choice. The stem’s prolonged aPTT with normal PT, failure of mixing study to correct, and markedly reduced FVIII activity (<1%) establish acquired hemophilia A with a high-titer inhibitor. For acute bleeding, human FVIII and cryoprecipitate are neutralized; DDAVP is ineffective; prednisone treats the underlying autoantibody but does not achieve hemostasis. Among the options, recombinant porcine FVIII (rpFVIII) is a guideline‑approved first‑line hemostatic agent for acquired hemophilia A, especially when bypassing agents are not listed. The item therefore points to a single best answer. No internal contradictions exist. Minor medical nuance: the optimal first‑line therapy is often a bypassing agent (rFVIIa or FEIBA), and rpFVIII’s efficacy is highest with low‑titer inhibitors; the stem omits inhibitor titer, but this does not invalidate the answer given the available choices. Medical accuracy is consistent with current ISTH/FDA guidance. Minimal fix: add a line stating ‘inhibitor titer is 8 Bethesda units’ to clarify high‑titer setting and reinforce that rpFVIII remains a recommended option.\",\n\"medical_accuracy_score\":  \t \t \t \t\"4\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (logically valid). Verdict: Keyed answer D is the correct best choice. The stem’s prolonged aPTT with normal PT, failure of mixing study to correct, and markedly reduced FVIII activity (<1%) establish acquired hemophilia A with a high-titer inhibitor. For acute bleeding, human FVIII and cryoprecipitate are neutralized; DDAVP is ineffective; prednisone treats the underlying autoantibody but does not achieve hemostasis. Among the options, recombinant porcine FVIII (rpFVIII) is a guideline‑approved first‑line hemostatic agent for acquired hemophilia A, especially when bypassing agents are not listed. The item therefore points to a single best answer. No internal contradictions exist. Minor medical nuance: the optimal first‑line therapy is often a bypassing agent (rFVIIa or FEIBA), and rpFVIII’s efficacy is highest with low‑titer inhibitors; the stem omits inhibitor titer, but this does not invalidate the answer given the available choices. Medical accuracy is consistent with current ISTH/FDA guidance. Minimal fix: add a line stating ‘inhibitor titer is 8 Bethesda units’ to clarify high‑titer setting and reinforce that rpFVIII remains a recommended option.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-010", "question": "A traveler returns from Malaysian Borneo with daily high-grade fevers and severe thrombocytopenia. Blood smear reveals high parasitemia with 'band form' trophozoites resembling Plasmodium malariae, but the clinical severity mimics Plasmodium falciparum. Which feature distinguishes the replication cycle of this pathogen from P. falciparum?", "options": ["Option A: 24-hour erythrocytic cycle", "Option B: 48-hour erythrocytic cycle", "Option C: 72-hour erythrocytic cycle", "Option D: Presence of a hypnozoite stage", "Option E: Preferential invasion of reticulocytes"], "answer": "A", "answer_index": 0, "explanation": "The pathogen is Plasmodium knowlesi, a zoonotic malaria. A key feature driving its potential for hyperparasitemia and severe disease is its unique 24-hour (quotidian) erythrocytic replication cycle. P. falciparum has a 48-hour cycle, and P. malariae has a 72-hour cycle. P. knowlesi does not have a hypnozoite stage (unlike P. vivax/ovale).", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Keyed answer is the correct best answer. The stem's geographic clue (Malaysian Borneo), daily high-grade fevers, severe thrombocytopenia, high parasitemia, and band-form trophozoites resembling P. malariae collectively point to Plasmodium knowlesi infection. The question asks specifically which feature distinguishes its replication cycle from P. falciparum. P. knowlesi's unique 24-hour erythrocytic cycle (quotidian fever pattern) is the distinguishing feature, making Option A correct. Alternative options are clearly inferior: B describes P. falciparum's own cycle; C describes P. malariae's 72-hour cycle; D (hypnozoites) does not distinguish from P. falciparum (which also lacks hypnozoites); and E (reticulocyte preference) is characteristic of P. vivax, not relevant to the P. knowlesi-P. falciparum comparison. No internal contradictions exist. Medical accuracy is excellent: P. knowlesi's 24-hour cycle, morphologic resemblance to P. malariae, and severe disease potential are well-established. The item is board-relevant and clinically realistic. Minimal fix: None required; item is ready for use.\",\"medical_accuracy_score\":   \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Keyed answer is the correct best answer. The stem's geographic clue (Malaysian Borneo), daily high-grade fevers, severe thrombocytopenia, high parasitemia, and band-form trophozoites resembling P. malariae collectively point to Plasmodium knowlesi infection. The question asks specifically which feature distinguishes its replication cycle from P. falciparum. P. knowlesi's unique 24-hour erythrocytic cycle (quotidian fever pattern) is the distinguishing feature, making Option A correct. Alternative options are clearly inferior: B describes P. falciparum's own cycle; C describes P. malariae's 72-hour cycle; D (hypnozoites) does not distinguish from P. falciparum (which also lacks hypnozoites); and E (reticulocyte preference) is characteristic of P. vivax, not relevant to the P. knowlesi-P. falciparum comparison. No internal contradictions exist. Medical accuracy is excellent: P. knowlesi's 24-hour cycle, morphologic resemblance to P. malariae, and severe disease potential are well-established. The item is board-relevant and clinically realistic. Minimal fix: None required; item is ready for use.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]